Kymera Investor Day Presentation Deck

TR Clinically Validated Targets Unlocked by E3 Ligase Differential Expression On target unwanted pharmacology limits clinical application ● Novel E3 Ligases to Drug a New Generation of Targets ● KYMERA Focused on determining the expression profiles of ~600 unique E3 ligases Patterns mapped in both disease and healthy contexts • Ability to match a target protein with appropriate E3 ligase based on expression and biology via a machine learning algorithm Vision to develop tissue-selective or tissue-restricted degraders to nable novel therapeutic opportunities ©2021 KYMERA THERAPEUTICS, INC. E3 LIGASES TARGETS CRBN CUL4A DDB1 XIAP LIGASE 1 LIGASE 2 LIGASE 3 LIGASE 4 RNF114 Mol. wt (kDa) DCAF 16 LIGASE 5 LIGASE 6 LIGASE 7 LIGASE 8 LIGASE 9 LIGASE 10 STAT3 IRAK4 TARGET 1 TARGET 2 TARGET 3 Increasing Abundance ooooooooº 000000 O 0000 TONSIL LIVER SPLEEN STOMACH BRAIN LUNG TESTIS DUODENUM KYMERA R&D DAY - December 16th, 2021 • ● SMALL INTESTINE. URINARY BLADDER... ESOPHAGUS GALL BLADDER TISSUES HEART THYROID ENDOMETRIUM NO FALLOPIAN TUBE. 6 KIDNEY SMOOTH MUSCLE PROSTATE APPENDIX PANCREAS OVARY PLACENTA •-. - RECTUM ADIPOSE TISSUE LYMPH NODE SALIVARY GLAND ADRENAL GLAND UNDISCLOSED Ubiquitous Restrictive Selective Source: Kymera's Proprietary E3 Expression Atlas PAGE 89

View entire presentation